| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
7.49(B) |
| Last
Volume: |
1,687,425 |
Avg
Vol: |
1,949,589 |
| 52
Week Range: |
$43.45 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
160,765 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$10,760,022 |
$18,676,003 |
| Total People Sold |
8 |
10 |
10 |
11 |
| Total Sell Transactions |
11 |
52 |
58 |
100 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conroy Kevin T |
President and CEO |
• • – |
2020-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,575 |
1,002,713 |
|
- |
|
| Stenhouse Mark |
President, Cologuard |
• – – |
2020-02-27 |
4 |
AS |
$80.27 |
$84,364 |
D/D |
(1,051) |
16,519 |
|
13% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-02-27 |
4 |
AS |
$80.27 |
$130,599 |
D/D |
(1,627) |
56,116 |
|
13% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2020-02-27 |
4 |
AS |
$80.27 |
$1,113,746 |
D/D |
(13,875) |
982,138 |
|
13% |
|
| Stenhouse Mark |
President, Cologuard |
• – – |
2020-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,262 |
17,570 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,436 |
57,743 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2020-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,337 |
996,013 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2020-02-25 |
4 |
AS |
$85.11 |
$1,541,768 |
D/D |
(18,115) |
966,676 |
|
-7% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-02-25 |
4 |
AS |
$85.11 |
$417,890 |
D/D |
(4,910) |
54,307 |
|
-7% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2020-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,325 |
984,791 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,300 |
59,217 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2020-02-19 |
4 |
AS |
$100.00 |
$2,735,600 |
D/D |
(27,356) |
10,194 |
|
-16% |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2020-02-19 |
4 |
OE |
$35.28 |
$620,776 |
D/D |
17,356 |
37,550 |
|
- |
|
| Orville Jacob A |
General Manager, New Ventures |
• – – |
2020-02-19 |
4 |
AS |
$100.68 |
$116,084 |
D/D |
(1,153) |
2,495 |
|
-16% |
|
| Orville Jacob A |
General Manager, New Ventures |
• – – |
2020-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,648 |
3,648 |
|
- |
|
| Hoof Torsten |
General Manager, International |
• – – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,091 |
5,914 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2020-01-16 |
4 |
AS |
$90.30 |
$903,000 |
D/D |
(10,000) |
8,653 |
|
-10% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2019-12-16 |
4 |
OE |
$13.96 |
$199,992 |
D/D |
11,440 |
950,466 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2019-12-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,334 |
18,653 |
|
- |
|
| Cole G Bradley |
General Manager - Diagnostics |
• – – |
2019-11-21 |
4 |
AS |
$80.38 |
$2,251,926 |
D/D |
(28,016) |
30,987 |
|
- |
|
| Casdin Eli |
Director |
– • – |
2019-11-08 |
4 |
A |
$0.00 |
$0 |
I/I |
450 |
225 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2019-10-30 |
4 |
A |
$60.60 |
$6,666 |
D/D |
110 |
59,109 |
|
- |
|
| Johnson Scott C. |
SVP - Research and Development |
• – – |
2019-09-12 |
4 |
AS |
$108.63 |
$383,138 |
D/D |
(3,527) |
12,311 |
|
- |
|
| Johnson Scott C. |
SVP - Research and Development |
• – – |
2019-09-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
15,838 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2019-07-31 |
4 |
AS |
$114.99 |
$1,176,487 |
D/D |
(10,000) |
34,181 |
|
- |
|
957 Records found
|
|
Page 17 of 39 |
|
|
0.75 (1.75%) 
